SCHEMBL5763779

SCHEMBL5763779

COc1cc2c(Oc3ccc(C4CCC5(CC4)OCCO5)cc3)c(C(=O)O)sc2cc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
POLB P06746 2/20 0.37
IKBKE Q14164 1/20 0.36
TBK1 Q9UHD2 1/20 0.36
ALOX15 P16050 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
HTT P42858 1/20 0.33
PRSS12 P56730 1/20 0.32
ESR1 P03372 2/20 0.32
HAO1 Q9UJM8 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32
MMP7 P09237 1/20 0.32
MMP13 P45452 1/20 0.32
MCHR1 Q99705 2/20 0.32
NPBWR1 P48145 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213831 0.89 RXRA (0.35) PRSS12ESR1MCHR1RXRACYP3A4
SCHEMBL4771980 0.88 L3MBTL1 (0.34) PRSS12ESR1MCHR1NPBWR1
SCHEMBL5210876 0.87 DYRK1A (0.38) ALDH1A1KMT2AMEN1PRSS12ESR1
SCHEMBL5216211 0.86 SMN1; SMN2 (0.39) ALDH1A1KDM4EKMT2AMEN1HTT
SCHEMBL5214032 0.86 SMN1; SMN2 (0.39) ALDH1A1KDM4EKMT2AMEN1HTT
SCHEMBL5214045 0.84 PDE4A (0.38) ALDH1A1KDM4EKMT2AMEN1PRSS12
SCHEMBL5252572 0.84 QDPR (0.49) ALDH1A1PRSS12
SCHEMBL4762803 0.84 NPC1 (0.38) IKBKETBK1PRSS12ESR1MCHR1
SCHEMBL5214658 0.82 PIK3CD (0.38) PRSS12ESR1MCHR1NPBWR1
SCHEMBL5254722 0.80 PDE4B (0.41) ALDH1A1PRSS12MMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636213-A1 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY Warner-Lambert Company LLC (US) 2006-03-22 EP disclosed
US-20040259926-A1 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents BRUENDL MICHELLE M (US) 2004-12-23 US disclosed
WO-2004108715-A1 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY WARNER-LAMBERT COMPANY LLC (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259926-A1 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents MALT1, CYP1B1, CYP4B1 ALDH1A1 110/4885POLB 4540/4885IKBKE 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.